



ASX / MEDIA RELEASE

13th February 2017

Foreshadowed Federal Court of Australia Proceeding – Update

Sydney, Australia: 13th February 2017 – On 30th January 2017, Sirtex Medical Limited (ASX:SRX) received a letter and draft statement of claim from law firm Portfolio Law, foreshadowing the commencement of a representative proceeding against the Company in the Federal Court of Australia.

In the letter, the Company was invited to enter into settlement discussions with the Plaintiff, pending commencement of the representative proceeding.

Sirtex has today declined that invitation.

If the foreshadowed representative proceeding is commenced, Sirtex will vigorously defend the proceeding.

About Sirtex Medical

Sirtex Medical Limited (ASX: SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries. For more information, please visit www.sirtex.com.

For further information, please contact:

Investor Enquiries:

Mr Darren Smith
CFO & Company Secretary
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406